Granulosa cell tumors of the ovary represent ∼5% of malignant ovarian tumors. The molecular pathogenesis of granulosa cell tumors is not known but 2 human granulosa cell tumor—derived cell lines, COV434 and KGN, exhibit constitutive activation of the nuclear factor kappa-B (NFκB)-signaling pathway. The proteasomal inhibitor, bortezomib, has a complex mode of action which includes inhibition of NFκB signaling. We examined the effect of bortezomib on the COV434 and KGN cells. The COV434 and KGN cells both showed a dose-dependent inhibition of cell proliferation and viability in response to bortezomib together with an increase in apoptosis. This was achieved at concentrations within the range seen for clinically responsive tumors. The NFκB constitutive activity was not however decreased. Genes were identified that were regulated in both lines in response to bortezomib. This study suggests that advanced granulosa cell tumors, as represented by the cell lines, may respond to bortezomib either alone or in combination with other agents.
Schumer ST, Cannistra SAGranulosa cell tumor of the ovary. J Clin Oncol. 2003;21:1180-1189.
2.
Fuller PJ, Chu S.Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol Metab. 2004;15:122-128.
3.
Chu S., Rushdi S., Zumpe ET, et al. FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Mol Hum Reprod. 2002;8:426-433.
4.
Kalfa N., Ecochard A., Patte C., et al. Activating mutations of the stimulatory G protein in juvenile ovarian granulosa cell tumors: a new prognostic factor? J Clin Endocrinol Metab. 2005;91:1842-1847.
5.
Chu S., Nishi Y., Yanase T., Nawata H., Fuller PJTransrepression of estrogen receptor β signalling by nuclear factor-KB in ovarian granulosa cells. Mol Endocrinol. 2004;18:1919-1928.
6.
Steinmetz R. , Wagoner HA, Zeng P., et al. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signalling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol. 2004;18:2570-2582.
7.
Adams J.The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2003;5:417-421.
8.
Teicher BA, Ara G., Herbst R., Palombella VJ, Adams J.The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5:2638-2645.
9.
Ling YH, Liebes L., Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res. 2003;9:1145-1154.
10.
Cusack , JC Jr, Liu R., Houston M., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res . 2001;61:3535-3540.
11.
Johnson TR, Stone K., Nikrad M., et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 2003;22:4953-4963.
12.
Nawrocki ST , Sweeney-Gotsch B., Takamori R., McConkey DJThe proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts . Mol Cancer Ther. 2004;3:59-70.
13.
Frankel A., Man S., Elliott P., Adams J., Kerbel RSLack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res. 2000;6:3719-3728.
14.
Mitsiades CS , McMillin D., Kotoula V., et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab. 2006;91:4013-4021.
15.
Wang Y., Chan S., Tsang BKInvolvement of inhibitory nuclear factor-kappaB (NFKB)-independent NFKB activation in the gonadotropic regulation of X-linked inhibitor of apoptosis expression during ovarian follicular development in vitro. Endocrinology . 2002;143:2732-2740.
16.
An J., Sun Y.-P., Adams J., Fisher M., Belldegrun A., Rettig MBDrug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF)α, and TNF-relatedapoptosis-inducing ligand in prostate cancer. Clin Cancer Res. 2003;9:4537-4545.
17.
Sunwoo JB, Chen Z., Dong G., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-KB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419-1428.
18.
Yin D., Zhou H., Kumagai T., et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM. Oncogene. 2005;24:344-354.
19.
Karin M.Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431-436.
20.
Mackay H., Hedley D., Major P., et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res. 2005;11:5526-5533.
21.
Zhu H., Zhang L., Dong F., et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene. 2005;24: 4993-4999.
22.
Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DRHeat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006 ;31:164-172.
23.
Schmitt E., Gehrmann M., Brunet M., Multhoff G., Garrido C.Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol. 2007;81:15-27.
24.
Garrido C., Brunet M., Didelot C., Zermati Y., Schmitt E., Kroemer G.Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties . Cell Cycle. 2006;5:2592-2601.
25.
Hosaka S., Nakatsura T., Tsukamoto H., Hatayama T., Baba H., Nishimura Y.Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo. Cancer Sci. 2006;97:623-632.
26.
Muchemwa FC, Nakatsura T., Ihn H., Kageshita T.Heat shock protein 105 is overexpressed in squamous cell carcinoma and extramammary Paget disease but not in basal cell carcinoma. Br J Dermatol . 2006;155:582-585.
27.
Kim R., Emi M., Tanabe K., Murakami S.Role of the unfolded protein response in cell death. Apoptosis . 2006;11:5-13.
28.
Lovat PE, Oliverio S., Corazzari M., et al. Induction of GADD153 and Bak: novel molecular targets of fenretinideinduced apoptosis of neuroblastoma. Cancer Lett. 2003 ;197: 157-163.
29.
Keen N., Taylor S.Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer . 2004;4:927-936.
30.
Sugimura M. , Sagae S., Ishioka S., Nishioka Y., Tsukada K., Kudo R.Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone. Oncology. 2004;66:53-61.
31.
Ruiz-Cortés ZT, Kimmins S., Monaco L., Burns KH, Sassone-Corsi P., Murphy BDEstrogen mediates phosphorylation of his-tone H3 in ovarian follicle and mammary epithelial tumor cells via the mitotic kinase, Aurora B. Mol Endocrinol. 2005;19:2991-3000.
32.
Eves EM, Shapiro P., Naik K., Klein UR, Trakul N., Rosner MRRaf kinase inhibitory protein regulates Aurora B kinase and the spindle checkpoint . Mol Cell. 2006;23:561-574.
